Cargando…
Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312988/ https://www.ncbi.nlm.nih.gov/pubmed/28178131 http://dx.doi.org/10.1097/MD.0000000000005913 |
_version_ | 1782508290226257920 |
---|---|
author | Chen, Linyan Wu, Xin Ma, Xuelei Guo, Linghong Zhu, Chenjing Li, Qingfang |
author_facet | Chen, Linyan Wu, Xin Ma, Xuelei Guo, Linghong Zhu, Chenjing Li, Qingfang |
author_sort | Chen, Linyan |
collection | PubMed |
description | BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in patients with soft tissue sarcoma. METHODS: The search and selection of eligible articles was conducted on PubMed and EMBASE. We applied hazard ratio (HR) and odd ratio (OR) to measure the correlation between SUVmax, MTV, and TLG with PFS and OS. The SUVmax was analyzed through subgroup in terms of histological grade and HR of posttreatment SUVmax was also assessed. RESULTS: Eleven studies with 582 patients were included. The pooled HRs of pretreatment SUVmax were 2.40 (95% CI: 1.38–4.17) for OS and 2.20 (95% CI: 1.47–3.30) for PFS. The HRs in terms of OS were 3.20 (95% CI: 1.71–5.98) based on MTV and 5.20 (95% CI: 2.34–11.56) based on TLG. Meanwhile, the predict results of pretreatment SUVmax on OR remained significant and the HRs of posttreatment SUVmax were 2.25 (95% CI: 1.33–3.80) for OS and 2.87 (95% CI: 1.81–4.55) for PFS. CONCLUSIONS: The pretreatment SUVmax, MTV, and TLG of (18)F-FDG PET-CT showed significant prognostic value for OS and the PET-CT can be used in identifying high-risk patients about progression and survival. The analysis for posttreatment SUVmax suggested PET-CT as a promising equipment in monitoring therapy response. |
format | Online Article Text |
id | pubmed-5312988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-53129882017-02-21 Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis Chen, Linyan Wu, Xin Ma, Xuelei Guo, Linghong Zhu, Chenjing Li, Qingfang Medicine (Baltimore) 5700 BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in patients with soft tissue sarcoma. METHODS: The search and selection of eligible articles was conducted on PubMed and EMBASE. We applied hazard ratio (HR) and odd ratio (OR) to measure the correlation between SUVmax, MTV, and TLG with PFS and OS. The SUVmax was analyzed through subgroup in terms of histological grade and HR of posttreatment SUVmax was also assessed. RESULTS: Eleven studies with 582 patients were included. The pooled HRs of pretreatment SUVmax were 2.40 (95% CI: 1.38–4.17) for OS and 2.20 (95% CI: 1.47–3.30) for PFS. The HRs in terms of OS were 3.20 (95% CI: 1.71–5.98) based on MTV and 5.20 (95% CI: 2.34–11.56) based on TLG. Meanwhile, the predict results of pretreatment SUVmax on OR remained significant and the HRs of posttreatment SUVmax were 2.25 (95% CI: 1.33–3.80) for OS and 2.87 (95% CI: 1.81–4.55) for PFS. CONCLUSIONS: The pretreatment SUVmax, MTV, and TLG of (18)F-FDG PET-CT showed significant prognostic value for OS and the PET-CT can be used in identifying high-risk patients about progression and survival. The analysis for posttreatment SUVmax suggested PET-CT as a promising equipment in monitoring therapy response. Wolters Kluwer Health 2017-02-10 /pmc/articles/PMC5312988/ /pubmed/28178131 http://dx.doi.org/10.1097/MD.0000000000005913 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 5700 Chen, Linyan Wu, Xin Ma, Xuelei Guo, Linghong Zhu, Chenjing Li, Qingfang Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title | Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title_full | Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title_fullStr | Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title_full_unstemmed | Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title_short | Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis |
title_sort | prognostic value of (18)f-fdg pet-ct-based functional parameters in patients with soft tissue sarcoma: a meta-analysis |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312988/ https://www.ncbi.nlm.nih.gov/pubmed/28178131 http://dx.doi.org/10.1097/MD.0000000000005913 |
work_keys_str_mv | AT chenlinyan prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis AT wuxin prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis AT maxuelei prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis AT guolinghong prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis AT zhuchenjing prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis AT liqingfang prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis |